Last reviewed · How we verify
carvedilol controlled release/lisinopril
Carvedilol controlled release/lisinopril combines a beta-blocker and an ACE inhibitor to reduce blood pressure and improve heart function.
Carvedilol controlled release/lisinopril combines a beta-blocker and an ACE inhibitor to reduce blood pressure and improve heart function. Used for Hypertension, Chronic heart failure.
At a glance
| Generic name | carvedilol controlled release/lisinopril |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | beta-blocker/ACE inhibitor combination |
| Target | beta-adrenergic receptors, angiotensin-converting enzyme |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Carvedilol, a non-selective beta-adrenergic receptor blocker, reduces heart rate and myocardial contractility, while lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure.
Approved indications
- Hypertension
- Chronic heart failure
Common side effects
- Dizziness
- Fatigue
- Cough
Key clinical trials
- Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. (PHASE4)
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab (PHASE2)
- COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria (PHASE3)
- Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure (PHASE3)
- The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial (PHASE3)
- The CLEVER Study - Coreg And Left Ventricular Mass Regression (PHASE3)
- The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carvedilol controlled release/lisinopril CI brief — competitive landscape report
- carvedilol controlled release/lisinopril updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI